Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8001513 | 0.95 | — | — | |
| SCHEMBL18638183 | 0.74 | HTT (0.56) | HTTGAASMN1; SMN2TSHRRAB9A | |
| SCHEMBL1100977 | 0.73 | HTT (0.46) | HTTGAASMN1; SMN2TSHRRAB9A | |
| SCHEMBL29341580 | 0.72 | PDK2 (0.33) | DRD4 | |
| SCHEMBL15980400 | 0.72 | MAOA (0.45) | DRD4DRD2 | |
| SCHEMBL1610177 | 0.72 | DRD4 (0.35) | DRD4HTTGAADRD2 | |
| SCHEMBL12250991 | 0.72 | HDAC8 (0.43) | HTTGAASMN1; SMN2TSHRRAB9A | |
| SCHEMBL16154696 | 0.72 | PDK2 (0.44) | HTTGAASMN1; SMN2TSHRRAB9A | |
| SCHEMBL18896278 | 0.72 | HTT (0.59) | HTTGAASMN1; SMN2TSHRRAB9A | |
| SCHEMBL12489993 | 0.72 | MAOA (0.45) | DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028411-A1 | COMBINATION THERAPY OF CDK7 INHIBITORS WITH OTHER ANTI-CANCER THERAPIES | QURIENT CO., LTD. (KR) | 2024-02-08 | — | — | WO | disclosed |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20230391790-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | TARO PHARMACEUTICALS INC. (CA) | 2023-12-07 | — | — | US | disclosed |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023205645-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| US-11773108-B2 | Indene derivatives useful in treating pain and inflammation | TARO PHARMACEUTICALS INC. (CA) | 2023-10-03 | — | — | US | disclosed |
| WO-2023175173-A1 | CDK7 INHIBITORS FOR ANTIVIRAL TREATMENT | QURIENT CO., LTD. (KR) | 2023-09-21 | — | — | WO | disclosed |
| EP-3555070-B1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2023107557-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | Kineta, Inc. (US) | 2023-06-15 | — | — | WO | disclosed |
| US-20120316185-A1 | Cyclohexyl Amide Derivatives as CRF Receptor Antagonists | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316185-A1 | Cyclohexyl Amide Derivatives as CRF Receptor Antagonists | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120142714-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20110263562-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporationn, a Delaware corporation | 2010-01-28 | — | — | US | disclosed |
| US-7598257-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-7566683-B2 | Ethylene derivatives and pesticides containing said derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| US-20070049495-A1 | Ethylene derivatives and pesticides containing said derivatives | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2007-03-01 | — | — | US | disclosed |
| WO-2001055136-A1 | BENZOXAZOLE DERIVATIVES AND THEIR USE AS PESTICIDES | SYNGENTA LIMITED (GB) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391790-A1 | INDENE DERIVATIVES USEFUL IN TREATING PAIN AND INFLAMMATION | IL1B, IL1A, LTB4R | DRD4 1804/4885HTT 2479/4885GAA 4780/4885 |
| US-20120316185-A1 | Cyclohexyl Amide Derivatives as CRF Receptor Antagonists | CRHR2, CRHR1, CRH | DRD4 1041/4885HTT 3462/4885GAA 3997/4885 |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDKL5, CDK15, CDK5 | DRD4 3489/4885HTT 4192/4885GAA 2264/4885 |
| US-20070049495-A1 | Ethylene derivatives and pesticides containing said derivatives | DDT, ECE1, EBPL | DRD4 185/4885HTT 3519/4885GAA 3315/4885 |
| US-20110263562-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | DRD4 4880/4885HTT 2514/4885GAA 782/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | DRD4 3613/4885HTT 3263/4885GAA 4524/4885 |
| US-20230374008-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | DRD4 4029/4885HTT 652/4885GAA 172/4885 |
| US-20100022522-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | DRD4 4444/4885HTT 3554/4885GAA 4364/4885 |
| US-11773108-B2 | Indene derivatives useful in treating pain and inflammation | IL1B, IL1A, LTB4R | DRD4 1784/4885HTT 2415/4885GAA 4786/4885 |
| US-20120142714-A1 | BICYCLIC COMPOUND | ACACA, ACACB, FABP4 | DRD4 4107/4885HTT 2526/4885GAA 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.